Hide

FocusBar

Subscribe to Premium Member
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 382.22   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
68% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 420.30 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt

F-Score: 5
Z-Score: 16
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.10
ABMD's Operating margin (%) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. ABMD: 10.10 )
ABMD' s 10-Year Operating margin (%) Range
Min: -91.7   Max: 10.1
Current: 10.1

-91.7
10.1
Net-margin (%) 9.1
ABMD's Net-margin (%) is ranked higher than
85% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. ABMD: 9.1 )
ABMD' s 10-Year Net-margin (%) Range
Min: -80.7   Max: 9.1
Current: 9.1

-80.7
9.1
Revenue Growth (%) 11.4
ABMD's Revenue Growth (%) is ranked higher than
93% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABMD: 11.4 )
ABMD' s 10-Year Revenue Growth (%) Range
Min: -3.5   Max: 11.4
Current: 11.4

-3.5
11.4
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

ABMD Guru Trades in Q2 2012

Paul Tudor Jones 23,600 sh (+116.51%)
RS Investment Management 887,980 sh (+72.02%)
Jim Simons 243,023 sh (+30.43%)
PRIMECAP Management 5,006,690 sh (-0.17%)
Pioneer Investments 373,372 sh (-23.32%)
» More
Q3 2012

ABMD Guru Trades in Q3 2012

Steven Cohen 18,060 sh (New)
Pioneer Investments 497,960 sh (+33.37%)
Paul Tudor Jones 31,100 sh (+31.78%)
PRIMECAP Management 5,006,690 sh (unchged)
Jim Simons 221,223 sh (-8.97%)
RS Investment Management 491,180 sh (-44.69%)
» More
Q4 2012

ABMD Guru Trades in Q4 2012

Paul Tudor Jones 39,100 sh (+25.72%)
Pioneer Investments 563,603 sh (+13.18%)
Jim Simons 234,323 sh (+5.92%)
PRIMECAP Management 5,297,690 sh (+5.81%)
RS Investment Management Sold Out
Steven Cohen 1,000 sh (-94.46%)
» More
Q1 2013

ABMD Guru Trades in Q1 2013

Steven Cohen 18,973 sh (+1797.3%)
PRIMECAP Management 5,751,990 sh (+8.58%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 437,683 sh (-22.34%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2011-06-30 Add 28.42%0.02%$14.65 - $18.94 $ 23.3339%3772973
PRIMECAP Management 2010-06-30 Add 20.11%0.01%$8.61 - $10.15 $ 23.33145%2551673
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Abiomed, Inc.

BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector Leon Cooperman,Michael Price - BSX And ABMD Highlight Increased Insider Buying In The Medical Technology Sector
In the past week we saw an increase in insider buying coming from the health care industry. Last week GuruFocus reported 31 different insider buys coming from 19 different health care-based companies. These buys spanned across the sector from research and development labs to pharmaceutical companies. The following four companies are all a part of the medical supply sector of the health care industry. They represent significant insider buys coming from one or more directors or corporate executives. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 63.00
ABMD's P/E(ttm) is ranked higher than
57% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. ABMD: 63.00 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 63

36.46
946.92
P/S 6.00
ABMD's P/S is ranked lower than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABMD: 6.00 )
ABMD' s 10-Year P/S Range
Min: 2.16   Max: 27.02
Current: 6

2.16
27.02
PFCF 56.80
ABMD's PFCF is ranked lower than
53% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. ABMD: 56.80 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 56.8

23.56
2462
EV-to-EBIT 47.6
ABMD's EV-to-EBIT is ranked lower than
53% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. ABMD: 47.6 )
ABMD' s 10-Year EV-to-EBIT Range
Min: 27   Max: 694.7
Current: 47.6

27
694.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.9
ABMD's Price/Median PS Value is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. ABMD: 0.9 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2
Current: 0.9

0.4
2
Earnings Yield (Greenblatt) 2.10
ABMD's Earnings Yield (Greenblatt) is ranked higher than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. ABMD: 2.10 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 2.1

0.1
3.7
Forward Rate of Return (Yacktman) -0.99
ABMD's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. ABMD: -0.99 )
ABMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.4   Max: -1.2
Current: -0.99

-3.4
-1.2

Business Description

Abiomed, Inc. was incorporated in Delaware. The Company is a provider of mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company's Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. It manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company's AbioCor Implantable Replacement Heart is the first completely self-contained artificial heart. Designed to sustain the body's circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Its main competitors are Getinge, Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, CircuLite, Inc., Terumo Heart, Inc. and CardiacAssist Inc. The healthcare industry, and thus its business, is subject to extensive federal, state, local and foreign regulation.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:AIO.Germany

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial